Sec. 7. Vaccine meetings; report on vaccine innovation
316 words·~1 min read·
/bill/114/s/2742/is/section-7A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
The Director of the Centers for Disease Control and Prevention shall ensure that appropriate staff within the relevant centers and divisions of the Office of Infectious Diseases, and others, as appropriate, coordinate with respect to the public health needs, epidemiology, and program planning and implementation considerations related to immunization, including with regard to meetings with stakeholders related to such topics. Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services (referred to in this section as the Secretary ), in collaboration with appropriate agencies or offices within the Department of Health and Human Services, including the National Institute of Allergy and Infectious Diseases and the Biomedical Advanced Research and Development Authority, shall issue to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives, and post publicly on the Internet website of the Department of Health and Human Services, a report on ways to promote innovation in the development of vaccines that minimize the burden of infectious disease.
The report described in paragraph
(1)shall review the current status of vaccine development and, as appropriate— consider the optimal process to determine which vaccines would be beneficial and how information on such vaccines is disseminated to key stakeholders; examine and identify whether obstacles exist that inhibit the development of beneficial vaccines; and make recommendations about how best to remove any obstacles identified under subparagraph
(B)in order to promote and incentivize vaccine innovation and development. In preparing the report under subsection (a), the Secretary may consult with— representatives of relevant Federal agencies and departments, including the Department of Defense and the Department of Veterans Affairs; academic researchers; developers and manufacturers of vaccines; medical and public health practitioners; representatives of patient, policy, and advocacy organizations; and representatives of other entities, as the Secretary determines appropriate.